Search

Your search for "vvos" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Reports Results of Seven-Month Provider-Based Marketing and Distribution Model Pilot

June 27, 2024

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is reporting on the positive results from seven-month pilot test. The multisite marketing initiative tested the core assumptions behind Vivos’ new affiliation and medical sleep specialist marketing and distribution model. […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Strategic Alliance, Private Equity Investment

June 12, 2024

Vivos Therapeutics (NASDAQ: VVOS) is a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (“OSA”) in adults). The company today announced the execution of a strategic marketing and distribution alliance with an operator of multiple […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q1 2024 Financial Report, Operational Update

May 15, 2024

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is reporting financial results and operating highlights for the first quarter 2024, the period ended March 31, 2024. Highlights of the report include Q1 2024 revenue reaching $3.4 million; gross […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Schedules Release of Q1 2024 Results, Conference Call

May 14, 2024

Vivos Therapeutics (NASDAQ: VVOS) is a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (“OSA”) in adults). The company today announced plans to release its first quarter 2024 financial results after market close on […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) CEO Discusses Medicare Reimbursement Approval for CARE Oral Medical Devices in Proactive Interview

April 10, 2024

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is spotlighted in a recent Proactive interview. During the interview, Vivos CEO Kirk Huntsman and Proactive host Steve Darling discuss the latest news from the company, which is the regulatory […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Achieves Milestone with CARE Oral Medical Devices Gaining Approval for Medicare Reimbursement

April 9, 2024

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, has obtained all required regulatory approvals so that its CARE oral medical devices can be reimbursed by Medicare. Calling this a “milestone achievement,” the company noted that millions of Medicare […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q4, FY 2023 Financial Report, Operational Update

April 1, 2024

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is reporting financial results and operating highlights for Q4 and full year 2023, for the period ended Dec. 31, 2023. The report noted that revenue came in at $3.2 million […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Schedules Release of Q4 and FY 2023 Results, Conference Call

March 28, 2024

Vivos Therapeutics (NASDAQ: VVOS) is a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (“OSA”) in adults). The company today announced it plans to release its fourth quarter and full year 2023 financial results […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Exercise of Warrants for ~$4M

February 15, 2024

Vivos Therapeutics (NASDAQ: VVOS) is a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (“OSA”)). The company today announced its entry into a definitive agreement for the immediate exercise of an outstanding common stock […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) CEO Highlights Favorable Market Developments Creating New Opportunities

February 13, 2024

Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, including all severities of obstructive sleep apnea (“OSA”) in adult patients, was spotlighted in a recent Proactive interview. During the interview, Vivos Therapeutics CEO Kirk Huntsman talked with Proactive […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Notes Key Market Developments Resulting in Growth Opportunities

February 6, 2024

Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, including all severities of obstructive sleep apnea (“OSA”) in adult patients, has noted significant favorable market developments resulting in opportunities for the company to reach out to more potential […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Reports Record Numbers Following First-Ever FDA 510(k) Clearance of Proprietary Oral Medical Devices

January 8, 2024

Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, including all severities of obstructive sleep apnea (“OSA”), has seen significant positive numbers since it received FDA 5109k) clearance of its CARE oral medical devices. The approval was the […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Host Pioneering Conference for Women in Medical, Dental Sectors

December 11, 2023

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is hosting a groundbreaking event for women in the medical and dental fields. The company announced that it is hosting a conference titled “Empowering Women to Champion Airway.” Scheduled for […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) CEO Discussed ‘Breakthrough’ FDA Clearance in Proactive Interview

November 30, 2023

Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is featured in a recent Proactive Investors interview. According to the announcement, Vivos Therapeutics CEO Kirk Huntsman joined Proactive host Steve Darling to discuss a “milestone” moment for the […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces First-Ever FDA Clearance for Treatment of Severe Obstructive Sleep Apnea Using Oral Device

November 29, 2023

Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, has been granted 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for treating severe obstructive sleep apnea (“OSA”) in adults using the exclusive Vivos removable Complete Airway […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Financial Report, Operational Update for Q3 2023

November 15, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults, is reporting financial results and operating highlights for the third-quarter and nine-month period ending Sept. 30, 2023. Highlights of the report include revenue of $3.3 million […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Plans to Release Q3 2023 Financial Results, Schedules Earnings Update

November 10, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults, is planning to release its Q3 2023 financial results after market close on Tuesday, Nov. 14, 2023. In addition, the company has scheduled a conference call […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Closing of Million-Dollar Private Placement

November 3, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults, has closed its previously announced private placement. According to the announcement, the placement will result in approximately $3.5 million net proceeds for the company after offering […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Pricing of $4M Private Placement

October 31, 2023

Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults. The company has announced its entry into a securities purchase agreement with an institutional investor for the purchase and sale of 980,393 shares of its […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Effect a Reverse Stock Split

October 26, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults, today announced that it will effect a 1-for-25 reverse stock split of its issued and outstanding common stock, effective with the opening of trading on Friday, Oct. 27, 2023. […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Partners with Lincare in New Nationwide Distribution Deal

October 24, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing-related sleep conditions arising from certain dentofacial abnormalities, has signed a U.S. nationwide distribution agreement with Lincare. The two companies have been […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) New Middle East-North Africa Distribution Deal Spotlighted in Proactive Interview

October 12, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing-related sleep conditions arising from certain dentofacial abnormalities, is spotlighted in a recent Proactive feature interview. During the interview, Vivos Therapeutics CEO […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Launch of DNA Clinical Trial

October 11, 2023

Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults. The company today announced that its flagship daytime-nighttime appliance (“DNA”) will be tested in a clinical trial at Stanford Medicine. According to the update, the protocol has been […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Strategic Collaboration, Expansion into MENA Region

October 5, 2023

Vivos Therapeutics (NASDAQ: VVOS) is a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary oral appliances for the treatment of breathing-related sleep disorders. The company today announced its entry into an exclusive distribution agreement with NOUM DMCC (“Noum”), a Dubai-based company focused on diagnostic testing and treatment […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Enters New Strategic Agreements with Ormco and On Demand Orthodontist

October 4, 2023

Vivos Therapeutics (NASDAQ: VVOS) is a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary oral appliances for the treatment of breathing-related sleep disorders. The company today announced two key strategic agreements that will expand Vivos’ current product line and are expected to create near-term additional revenue opportunities. […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces NYT Best-Selling Author James Nestor as Keynote Speaker for Upcoming Breathing Wellness Conference

October 2, 2023

Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective, proprietary oral appliances for the treatment of breathing-related sleep disorders, today announced that world renowned author James Nestor will headline a multidisciplinary list of distinguished speakers at the Company’s Fifth Annual Breathing Wellness Conference. This […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q2, YTD 2023 Financial, Operational Report

August 17, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep conditions arising from certain dentofacial abnormalities, is reporting its financial and operating results for the second quarter and six-month […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Date for Rescheduled Q2 2023 Financial Results Conference Call

August 16, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep conditions arising from certain dentofacial abnormalities, has announced the date for the conference call to discuss financial results for […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Plans to Reschedule Q2 2023 Financial Results Conference Call

August 15, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep conditions arising from certain dentofacial abnormalities, has rescheduled its conference call to discuss financial results for the second quarter […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Plans to Release Q2 2023 Financial Numbers, Schedules Conference Call

August 11, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing-related sleep issues arising from certain dentofacial abnormalities, anticipates releasing its second quarter 2023 financial results on Aug. 14, 2023, after the […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q1 2023 Financial Numbers, Corporate Update

June 9, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing-related sleep issues arising from certain dentofacial abnormalities, has released a financial report and company update for the first quarter, the period […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Plans to Release Q1 2023 Financial Numbers, Host Earnings Call

June 7, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing-related sleep issues arising from certain dentofacial abnormalities, anticipates releasing its first quarter 2023 financial results on June 8, 2023, after the […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Featured in Proactive Studio Podcast

May 16, 2023

Vivos Therapeutics (NASDAQ: VVOS) chairman and CEO Kirk Huntsman recently joined Natalie Stoberman from the Proactive Studio to discuss how the company’s POD device performed a highly effective rate in treating migraine headaches in a clinical study. During the interview, Huntsman said that the study showed 92% of patients reporting complete resolution of their symptoms, […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces New Strategic Initiatives

May 9, 2023

Vivos Therapeutics (NASDAQ: VVOS) today announced it has implemented a broad set of initiatives aimed at improving operational efficiencies, reducing expenses and positioning Vivos to take advantage of current growth opportunities. According to the update, the initiatives touch most aspects of Vivos’ operations and include expense reductions, product suite expansion and organizational changes that included […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Reports on ‘Game-Changing’ Appliance Treatment for Migraines

May 1, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep issues arising from certain dentofacial abnormalities, is reporting on the results of a recent clinical observational study. According to […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q4, FY Financial and Operational Report

March 31, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical device and technology company that delivers training and a full line of highly effective proprietary oral appliances for the treatment of breathing related sleep disorders in adults, including mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, is reporting its financial results and operating highlights for the fourth quarter and full […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Schedules Release of Q4 and FY 2022 Results, Conference Call

March 30, 2023

Vivos Therapeutics (NASDAQ: VVOS) is a medical device and technology company that delivers training and a full line of highly effective proprietary oral appliances for the treatment of breathing related sleep disorders in adults. The company announced plans to release its fourth quarter and full year 2022 financial results after market close today, Thursday, March […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Participate at 35th Annual ROTH Conference

March 8, 2023

Vivos Therapeutics (NASDAQ: VVOS) is a medical device and technology company that delivers training and a full line of highly effective proprietary oral appliances for the treatment of breathing-related sleep disorders in adults. The company today announced that its chairman and CEO Kirk Huntsman and CFO Brad Amman will participate at the 35th Annual ROTH […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Expands Product Portfolio, Revenue Potential Through Strategic Acquisition

March 1, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical device and technology company that delivers training and a full line of highly effective proprietary oral appliances for the treatment of breathing related sleep disorders, today announced its acquisition of certain U.S. and international patents, product rights and other miscellaneous intellectual property from Advanced Facialdontics LLC (“AFD”), which holds […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Participation at Emerging Growth Conference

February 22, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults, will be presenting at today’s Emerging Growth Conference. The company announced that chair and CEO Kirk Huntsman will be participating in the conference; Huntsman’s […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).